Founded in 1989, Propharma Co., Ltd. is a pharmaceutical industry platform under Hengdian Group, a famous private enterprise, and a listed company on the main board of Shenzhen Stock Exchange. Headquartered in Hengdian, Zhejiang Province, the company has a registered capital of 1.178 billion yuan and more than 7,000 employees.
The company is the vice president of China Medical Insurance Chamber of Commerce, Zhejiang Pharmaceutical Industry Association, the executive director of Zhejiang Pharmaceutical Society, and the governing unit of Shanghai Yangtze River Delta Business Innovation Research Institute. In the latest announcement of the Ministry of Industry and Information Technology, the top 100 pharmaceutical industry enterprises ranked 36th, the export of chemical raw materials ranked second in the country, and China’s top 5 small molecule CDMO enterprises; It won the top 100 list of “China’s most Growth listed companies” and was selected as the “Eagle Action” cultivation enterprise in Zhejiang Province.
The company is mainly engaged in API, CDMO, pharmaceutical, medical and cosmetic raw materials, etc. The company has 7 API production factories (including 5 chemical synthesis factories, 2 biological fermentation factories) and 2 preparation production factories. Products involved in cardiovascular and cerebrovascular, anti-infection, psychiatric, anti-tumor and other therapeutic fields.
The production base is distributed in Dongyang, Zhejiang, Weifang, Shandong, Dongzhi, Anhui and Quzhou, Zhejiang. Since 2007, the company’s quality system has passed the official audits of China’s NMPA, the US FDA, the EU EMEA and Japan’s PMDA, and has become a domestic characteristic API head enterprise, and continues to promote the continuous, automated, digital and intelligent construction of pharmaceutical manufacturing.
With the advantages of R&D and efficient manufacturing, CDMO business has formed a long-term strategic partnership with top innovative pharmaceutical companies at home and abroad, achieved a one-stop full range of services, and continued to maintain high growth. Established the well-known domestic “Beshin” “Tianliwei” brand “, the first high-end slow release has opened the American market, to achieve rapid development.
The company implements the development strategy of “making fine raw materials, strengthening CDMO, making good drugs, and expanding medical beauty”, with annual R&D investment accounting for more than 5% of the company’s revenue, and creating several leading technology platforms and support platforms in China and even the world. At present, the company has more than 1,300 research and development personnel.
The company has set up a science and technology Advisory committee, and Shanghai Jiao Tong University, Shanghai University of Applied Technology and Zhejiang University of Technology have jointly established relevant biological, chemical and engineering technology platforms to enable technological innovation and intelligent manufacturing.
The company pursues the development concept of “strong science and technology research and development, high standard compliance, low cost manufacturing”, and is committed to becoming a global scientific and technological pharmaceutical manufacturing leader.
Prop Pharmaceutical (000739.SZ) announced that recently, the company’s holding subsidiary Zhejiang Prok Kangyu Pharmaceutical Co., LTD. (referred to as “Kangyu Pharmaceutical”) received the “Drug Registration Certificate” of oseltamivir phosphate capsule issued by the State Drug Administration.
Oseltamivir phosphate capsules are used for the treatment of influenza A and B in adults and children 1 year and older within 48 hours of the first onset of symptoms; It is also used for the prevention of influenza A and B in adults and adolescents aged 13 years and older.
According to relevant data, the domestic clinical hospital market size of oseltamivir phosphate capsule in 2023 is 300 million pieces, with sales of 1.53 billion yuan. As of the disclosure date of this announcement, the cumulative R&D cost of oseltamivir phosphate capsules was RMB 6.203,700 yuan.
The company’s products were approved for listing in accordance with Class 4 chemical drugs and deemed to have passed the generic drug consistency evaluation. The product has the competitive advantage of API + preparation integration.
The approval of the product indicates that the company has the domestic sales qualification, enriches the company’s product line in the field of antiviral, further optimizes the company’s preparation product structure, enhances the company’s preparation market competitiveness, and plays a positive role in the company’s future business development.
Related topics
